Sagimet Biosciences Inc. cotiza a 8.80 USD y tiene una capitalización bursátil de $624M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, onc…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.33 | $-0.29 |
| Estimado | $-0.26 | $-0.27 | $-0.35 | $-0.40 |
| Sorpresa | — | — | +5.7% | +27.5% |
| Métrica | SGMT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -45.8% | -40.4% | -5.4% |
| ROA | -43.8% | -32.0% | -11.8% |
| Current Ratio | 22.82 | 2.84 | +19.98 |
| Debt / Equity | — | 0.28 | — |